Clinical trials
Aneurysm, False trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
16 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 5 |
| Recruiting | 4 |
| Unknown status | 3 |
| Temporarily not available | 1 |
| Not yet recruiting | 1 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| W.L.Gore & Associates | 2 |
| Centre Hospitalier Universitaire de Nice | 1 |
| Chinese Academy of Medical Sciences, Fuwai Hospital | 1 |
| Cook Research Incorporated | 1 |
| Hopital de l'Enfant-Jesus | 1 |
| LVD Biotech S.L | 1 |
| Maastricht University Medical Center | 1 |
| Phenox GmbH | 1 |
| Rigshospitalet, Denmark | 1 |
| Rodney A. White, M.D. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Aneurysm, False | 16 |
| Aortic Dissection | 4 |
| Aneurysm | 3 |
| Aortic Aneurysm, Thoracic | 3 |
| Constriction, Pathologic | 3 |
| Penetrating Atherosclerotic Ulcer | 3 |
| Dissection, Thoracic Aorta | 2 |
| Hemorrhage | 2 |
| Vascular Malformations | 2 |
| Abdominal Injuries | 1 |
Trials
Showing 1 to 16 of 16. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.